TPO and autoimmune thrombocytopenic purpura: Preliminary data from the McMaster and Norwegian ITP registries demonstrate that the proportion of adult ITP patients who have received first-line therapy, rituximab, at least one TPO-RA, and splenectomy ranges from 3.1% to 4.7% [117].